Active	Status	Sponsor type	Region	Phase	Filter
10 Active 0 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Smith, Adam
NCT04641143: Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder	Recruiting	3	700	US	Troriluzole, Placebo	Biohaven Pharmaceuticals, Inc.	Obsessive-Compulsive Disorder	06/25	06/25
NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Recruiting	3	375	Europe, US, RoW	Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo	Suven Life Sciences Limited, Suven Life Sciences Ltd	Agitation, Alzheimer's Type Dementia	01/25	01/25
NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder	Completed	2	15	US	ANC-501	Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.	Major Depressive Disorder	08/23	10/23
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia	Active, not recruiting	2	350	US	LB-102	LB Pharmaceuticals Inc.	Schizophrenia	12/24	05/25
NTS PAS, NCT04095481: Obalon Navigation/Touch System Post-Approval Study	Recruiting	N/A	1600	US	Obalon Navigation/Touch System	Obalon Therapeutics, Inc.	Obesity	05/23	05/23
Henry, Bryanna
NTS PAS, NCT04095481: Obalon Navigation/Touch System Post-Approval Study	Recruiting	N/A	1600	US	Obalon Navigation/Touch System	Obalon Therapeutics, Inc.	Obesity	05/23	05/23